Business Summary
At the end of 2021, the group had a portfolio of 3 products, including 1 in phase II of clinical development (APD403; treatment of chemically induced nausea and vomiting) and 2 in pre-launch phase: BARHEMSYS (treatment of nausea and postoperative vomiting) and BYFAVO (benzodiazepine sedative for use in invasive medical procedures in adults, such as colonoscopy and bronchoscopy).
Number of employees: 76
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Bolinder
CEO | Chief Executive Officer | - | 15-07-31 |
Scott A. Byrd
CHM | Chairman | 54 | 15-02-28 |
Gabriel Fox
CTO | Chief Tech/Sci/R&D Officer | - | 07-12-31 |
Debra M. Hussain
PRN | Corporate Officer/Principal | - | 21-05-18 |
Corporate Secretary | - | 20-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ed Borkowski
BRD | Director/Board Member | 64 | 18-02-28 |
John Brown
BRD | Director/Board Member | 69 | 18-02-28 |
Scott A. Byrd
CHM | Chairman | 54 | 15-02-28 |
- | - | ||
Director/Board Member | - | - |
Company contact information
Acacia Pharma Group Ltd.
The Officers' Mess Royston Road
CB22 4QH, Duxford
+44 1223 919760
http://www.acaciapharma.com